These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 17397707)

  • 1. Managing metastatic bone pain: the role of bisphosphonates.
    Gralow J; Tripathy D
    J Pain Symptom Manage; 2007 Apr; 33(4):462-72. PubMed ID: 17397707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer: bisphosphonate therapy for metastatic bone disease.
    Body JJ
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6258s-6263s. PubMed ID: 17062710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
    J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of bisphosphonates in early breast cancer.
    Paterson AH
    Oncologist; 2006; 11 Suppl 1():13-9. PubMed ID: 16971735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approaches to managing bone metastases from breast cancer: the role of bisphosphonates.
    Mystakidou K; Katsouda E; Stathopoulou E; Vlahos L
    Cancer Treat Rev; 2005 Jun; 31(4):303-11. PubMed ID: 16039956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibandronate: its role in metastatic breast cancer.
    Cameron D; Fallon M; Diel I
    Oncologist; 2006; 11 Suppl 1():27-33. PubMed ID: 16971737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonates: clinical experience.
    Coleman RE
    Oncologist; 2004; 9 Suppl 4():14-27. PubMed ID: 15459426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal management of metastatic bone disease.
    Major P
    Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching breast cancer patients with progressive bone metastases to third-generation bisphosphonates: measuring impact using the Functional Assessment of Cancer Therapy-Bone Pain.
    Broom R; Du H; Clemons M; Eton D; Dranitsaris G; Simmons C; Ooi W; Cella D
    J Pain Symptom Manage; 2009 Aug; 38(2):244-57. PubMed ID: 19364633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of bisphosphonates in breast cancer.
    Coleman RE
    Breast; 2004 Dec; 13 Suppl 1():S19-28. PubMed ID: 15585379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacotherapy of bone metastases in breast cancer patients.
    Petrut B; Simmons C; Broom R; Trinkaus M; Clemons M
    Expert Opin Pharmacother; 2008 Apr; 9(6):937-45. PubMed ID: 18377337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging role of bisphosphonates in the clinic--antitumor activity and prevention of metastasis to bone.
    Lipton A
    Cancer Treat Rev; 2008; 34 Suppl 1():S25-30. PubMed ID: 18486347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trials in metastatic breast cancer to bone: past--present--future.
    Body JJ
    Can J Oncol; 1995 Dec; 5 Suppl 1():16-27. PubMed ID: 8853520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current use of bisphosphonates in clinical oncology].
    Vrbanec D; Plestina S; Belev B; Unusić J; Pavlinić-Diminić V
    Lijec Vjesn; 1999; 121(9-10):296-301. PubMed ID: 19658372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens.
    Conte P; Guarneri V
    Oncologist; 2004; 9 Suppl 4():28-37. PubMed ID: 15459427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence.
    Smith MR
    Cancer Treat Rev; 2005; 31 Suppl 3():19-25. PubMed ID: 16229955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse effects of bisphosphonates: current issues.
    Diel IJ; Bergner R; Grötz KA
    J Support Oncol; 2007; 5(10):475-82. PubMed ID: 18240669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials.
    Machado M; Cruz LS; Tannus G; Fonseca M
    Clin Ther; 2009 May; 31(5):962-79. PubMed ID: 19539097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.